Mizuho Markets Americas LLC Cuts Stock Position in Haemonetics Corporation $HAE

Mizuho Markets Americas LLC lessened its position in shares of Haemonetics Corporation (NYSE:HAE) by 65.5% in the 1st quarter, HoldingsChannel reports. The fund owned 192,314 shares of the medical instruments supplier’s stock after selling 364,314 shares during the period. Mizuho Markets Americas LLC’s holdings in Haemonetics were worth $10,839,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. State of Wyoming boosted its stake in Haemonetics by 90.4% in the first quarter. State of Wyoming now owns 5,234 shares of the medical instruments supplier’s stock valued at $295,000 after acquiring an additional 2,485 shares in the last quarter. First Trust Advisors LP acquired a new position in shares of Haemonetics during the first quarter worth $5,087,000. Westpac Banking Corp increased its position in shares of Haemonetics by 35.5% during the first quarter. Westpac Banking Corp now owns 4,852 shares of the medical instruments supplier’s stock worth $273,000 after purchasing an additional 1,271 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Haemonetics by 21.3% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,326,057 shares of the medical instruments supplier’s stock valued at $74,731,000 after purchasing an additional 233,119 shares during the last quarter. Finally, Heartland Advisors Inc. lifted its holdings in shares of Haemonetics by 13.3% during the 1st quarter. Heartland Advisors Inc. now owns 85,000 shares of the medical instruments supplier’s stock valued at $4,791,000 after purchasing an additional 10,000 shares during the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on HAE. Barrington Research dropped their target price on Haemonetics from $94.00 to $89.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 12th. Weiss Ratings upgraded Haemonetics from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, June 25th. Bank of America raised Haemonetics from a “neutral” rating to a “buy” rating and raised their price target for the stock from $72.00 to $80.00 in a report on Friday, May 22nd. Wall Street Zen upgraded Haemonetics from a “hold” rating to a “buy” rating in a research note on Saturday, May 23rd. Finally, Mizuho upped their price objective on shares of Haemonetics from $85.00 to $90.00 and gave the company an “outperform” rating in a report on Wednesday, July 15th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $78.89.

Haemonetics Stock Down 0.7%

Shares of HAE stock opened at $77.49 on Friday. The stock’s 50-day simple moving average is $72.31 and its 200-day simple moving average is $66.08. The company has a debt-to-equity ratio of 1.53, a quick ratio of 1.87 and a current ratio of 2.95. The firm has a market capitalization of $3.52 billion, a PE ratio of 38.36, a P/E/G ratio of 1.57 and a beta of 0.52. Haemonetics Corporation has a fifty-two week low of $47.31 and a fifty-two week high of $87.32.

Haemonetics (NYSE:HAE) last released its earnings results on Thursday, May 7th. The medical instruments supplier reported $1.29 EPS for the quarter, topping analysts’ consensus estimates of $1.28 by $0.01. The firm had revenue of $346.35 million during the quarter, compared to the consensus estimate of $336.83 million. Haemonetics had a return on equity of 27.30% and a net margin of 7.29%.The company’s revenue was up 4.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.24 earnings per share. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. Equities analysts expect that Haemonetics Corporation will post 5.21 earnings per share for the current year.

Haemonetics Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.